- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- dasotraline, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 65
- States / cities
- Beverly Hills, California • Encino, California • Escondido, California + 52 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
- Interventions
- dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • Atlanta, Georgia + 2 more
- Conditions
- Binge Eating Disorder
- Interventions
- Dasotraline, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 43
- States / cities
- Beverly Hills, California • Encino, California • Garden Grove, California + 39 more
- Conditions
- Binge Eating Disorder
- Interventions
- Dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 52 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo Comparator
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 43
- States / cities
- Dothan, Alabama • National City, California • Paramount, California + 37 more
- Conditions
- Binge Eating Disorder
- Interventions
- dasotraline 4mg, dasotraline 6mg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 44 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 36
- States / cities
- Dothan, Alabama • Culver City, California • Wildomar, California + 30 more
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- SEP-225289, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 31
- States / cities
- Encino, California • Garden Grove, California • Irvine, California + 28 more
- Conditions
- Adult Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- dasotraline 4mg, Placebo
- Drug · Other
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 2 more
- Conditions
- Pediatric Attention Deficit Hyperactivity Disorder
- Interventions
- Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Colorado Springs, Colorado • Hialeah, Florida + 7 more